Dr. Jonathan Trent on Pembrolizumab in Advanced Sarcomas

Jonathan C. Trent, MD, PhD
Published: Tuesday, Aug 09, 2016



Jonathan C. Trent, MD, PhD, professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discuses a phase II study of pembrolizumab in advanced sarcomas,
 
There were several abstracts presented at the ASCO 2016 Annual Meeting that focused on immunotherapy in sarcoma. One of the most interesting looked at SARC028, a phase II study of the anti-PD-1 antibody pembrolizumab in patients with advanced sarcomas, said Trent.
 
The overall objective response rate 19% and the disease free rate at 4 months was 44% compared to a historical control of 20%. Thirty-three percent of patients with undifferentiated pleomorphic sarcoma, and dedifferentiated liposarcoma treated on this trial had a reduction in tumor size.

This clearly shows that  pembrolizumab has activity as a single-agent, said Trent. There is future potential to use it in combination in sarcoma as well, he said.
 


Jonathan C. Trent, MD, PhD, professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discuses a phase II study of pembrolizumab in advanced sarcomas,
 
There were several abstracts presented at the ASCO 2016 Annual Meeting that focused on immunotherapy in sarcoma. One of the most interesting looked at SARC028, a phase II study of the anti-PD-1 antibody pembrolizumab in patients with advanced sarcomas, said Trent.
 
The overall objective response rate 19% and the disease free rate at 4 months was 44% compared to a historical control of 20%. Thirty-three percent of patients with undifferentiated pleomorphic sarcoma, and dedifferentiated liposarcoma treated on this trial had a reduction in tumor size.

This clearly shows that  pembrolizumab has activity as a single-agent, said Trent. There is future potential to use it in combination in sarcoma as well, he said.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x